Company profile
No filing profile on file. The context below is drawn from our coverage.
- Type
- Company
- Analyses
- 1
- Angles
- Decision Forks
Decisions on record
One verified Decision Record on AbbVie, and the casebook each one belongs to.
| Fork date | Decision type | What AbbVie chose | Where it stood | The story | Casebook |
|---|---|---|---|---|---|
| 2016 | The Fork | Buy Stemcentrx with earn-out | terminated the Rova-T program and recorded an additional $1.0 billion impairment of remaining IPR&D (2019) | Read the story → | The Fork Casebook → |
Run one of these yourself
The decisions AbbVie faced, as kits you can run.
Each pack takes one of these decisions and gives you the framework, a deck for the room, a model that resolves to one number, and the sourced cases behind it. $499, one-time.